New Plymouth Campaign Urges Residents to Eat More Local Seafood - UK Fishing Industry - The Fishing Daily - Irish, UK and European Fishing Industry News A new Plymouth campaign urges residents to eat more local seafood by reconnecting communities with the city’s fleet and promoting locally landed fish

New Plymouth Campaign Urges Residents to Eat More Local Seafood
thefishingdaily.com/uk-fishing-i...

#ukfishingnews #ukfishingindustry #fishingnewsEngland #commercialfishingnews #fishingnews #dailyfishingnews #Plymouth #ATasteoftheSalt #PlymouthFishingandSeafoodAssociation #PFSA

VesselAlert
Name: FWN ARCTIC
MMSI: 244130525
Callsign: PFSA
Type: Cargo
Flag: Netherlands
Seen: 09-Mar-2026 13:39:43 CET
Status: under way using engine
Speed: 13.0 kts
Heading: 220 deg
Dest.: BE ANR
Distance: 80.3 nm
Signal RSSI: -22.1 dBFS
Ship AIS VesselAlert © kx1t - link

VesselAlert
Name: FWN ARCTIC
MMSI: 244130525
Callsign: PFSA
Type: Cargo
Flag: Netherlands
Seen: 07-Mar-2026 17:10:56 CET
Speed: 13.5 kts
Heading: 321 deg
Dest.: BE ANR
Distance: 37.2 nm
Signal RSSI: 0.0 dBFS
Ship AIS VesselAlert © kx1t - link

Plymouth Campaign Launches to Restore Fish Market Visibility - UK Fishing Industry - The Fishing Daily - Irish, UK and European Fishing Industry News The Plymouth Fishing & Seafood Association campaign launches to restore fish market visibility and improve local access for the fleet

Plymouth Campaign Launches to Restore Fish Market Visibility
thefishingdaily.com/uk-fishing-i...

#ukfishingnews #ukfishingindustry #fishingnewsEngland #commercialfishingnews #fishingnews #dailyfishingnews #Plymouth #ATasteoftheSalt #PlymouthFishingandSeafoodAssociation #PFSA

Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering Profusa (Nasdaq: PFSA) will withdraw its Form S-1 registration and will not proceed with the previously contemplated $15 million public offering.The company said it will instead pursue a smaller, more focused offering to support projected Europe Lumee Oxygen revenue beginning Q2 2026 and investment in its Mayo collaboration to accelerate U.S. plans.

#PFSA Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering

www.stocktitan.net/news/PFSA/profusa-to-wit...

The Best Match Analysis and Scouting Courses in the World “From a PFSA-Certified Analyst: A Step-by-Step Educational Pathway from Beginner Level to the UEFA Elite Programme.”

The Best Match Analysis and Scouting Courses in the World
medium.com/@mralikacan/...

#scout #scouting #football #pfsa #football #analysis #tactic #soccer

Dünyanın En İyi Maç Analizi Ve Scouting Kursları “PFSA sertfikalı bir analistten; başlangıç seviyesinden UEFA Elite programına kadar adım adım eğitim rotası.”

Dünyanın En İyi Maç Analizi Ve Scouting Kursları medium.com/p/d%C3%BCnya...

#futbol #scouting #scout #Pfsa #uefa #football #analiz

Breaking News: ( NASDAQ: #PFSA ) US Companies Moving the Markets, Evening edition <br>Mon, Feb 09, 2026 as of 4:00 pm ET

Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue Profusa (Nasdaq: PFSA) launched the Lumee tissue oxygen Healthcare Research offering on Jan 16, 2026, making research-use-only (RUO) Lumee kits and a service-enabled platform commercially available for immediate deployment to contract research organizations (CROs).The initiative targets the global CRO market, cited at $47.9 billion in 2025 with a projected ~7% CAGR, and is intended to generate near-term service revenue by enabling continuous, real-time tissue oxygen measurements for preclinical, translational, organ-on-chip, and other R&amp;D applications. Profusa named Sean Givens to lead commercialization as Head of Government and Healthcare Research Business.

#PFSA Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue

www.stocktitan.net/news/PFSA/profusa-launch...

📢 Stocks Trending NOW: #CETX #RARE #BIDU #EKSO #PFSA #MREO #DRMA #BNAI #CROX #NEM

Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 Profusa (Nasdaq: PFSA) announced a restructuring of its Senior Secured Convertible Notes on December 30, 2025 to provide greater repayment flexibility and reduce dilution.Key changes include an increase in the conversion floor price to $0.35 from $0.10, elimination of mandatory cash and equity amortization payments originally scheduled to begin Q1 2026, a final scheduled payment due at note maturity (18 months after issuance), and higher mandatory ELOC payments that rise from 17.5% to 33% for shares issued under the existing registration statement and to 50% for shares issued under any Form S-1 filed after this date.

#PFSA Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35

www.stocktitan.net/news/PFSA/profusa-restru...

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 Profusa (Nasdaq: PFSA) presented FDA-advised pilot phase results at Paris Vascular Insights on Dec 13, 2025 showing its Lumee™ implantable hydrogel sensors met primary end points for long-term tissue oxygen monitoring in peripheral artery disease (PAD) patients.Key facts: 15 PAD patients were followed up to 12 months with visits on days 2, 10, 90, 180, 365; Lumee traces strongly correlated with transcutaneous partial pressure of oxygen (tcpO2); sensors remained functional up to one year; no sensor placement–related adverse events were reported. Results are said to support a potential U.S. FDA submission and a planned EU commercialization start in early 2Q 2026.

#PFSA Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

www.stocktitan.net/news/PFSA/profusa-u-s-st...

Profusa Announces Third Quarter Business and Financial Highlights Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a

#PFSA Profusa Announces Third Quarter Business and Financial Highlights

www.stocktitan.net/news/PFSA/profusa-announ...

Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches Profusa (Nasdaq: PFSA) outlined a commercialization and revenue roadmap anchored by its Lumee tissue-integrated biosensor platform. The company expects EU commercialization in 2Q 2026 with CE GMED certification anticipated in late 1Q 2026 and projects €600–€800 per procedure and equipment revenue of €30,000–€40,000 per center per year. Profusa stated ~35% European population coverage via intended distributors and forecasted potential revenue of $0.5–$2M in 2026, $9–$13M in 2027, and $200–$250M by 2030.The company plans US Lumee oxygen launch in 1Q 2027 and EU Lumee glucose in mid-2027, and cited addressable markets and additional analytes that could contribute to 2030 targets.

#PFSA Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches

www.stocktitan.net/news/PFSA/profusa-outlin...

Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026 Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health

#PFSA Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026

www.stocktitan.net/news/PFSA/profusa-comple...

Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe Profusa (Nasdaq: PFSA) announced on October 22, 2025 an expansion of commercial distribution for its Lumee Oxygen platform in Europe via a letter of intent with Angiopro GmbH.Initial target launch markets are Germany, Benelux, Austria, the United Kingdom, and Scandinavia. Combined with a prior Spain distributor, Profusa estimates distributor channels now cover ~35% of the European Union population. The company cites ~300,000 annual endovascular procedures in Europe and a global addressable market of $10.5B+ across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia.

#PFSA Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe

www.stocktitan.net/news/PFSA/profusa-expand...

Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 annual endovascular procedures BERKELEY, Calif, Oct. 15, 2025 (GLOBE NEWSWIRE)

#PFSA Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe

www.stocktitan.net/news/PFSA/profusa-expand...

Profusa Invests Additional $1 Million in Digital Treasury Assets Profusa (Nasdaq: PFSA) announced on October 7, 2025 a second $1 million investment in digital treasury assets as part of its treasury management strategy to hedge macroeconomic uncertainty. The company said the strategy supports commercial and development plans for its Lumee continuous biochemical monitoring platform and aims to maintain capital for AI-driven digital health initiatives. Profusa noted continued collaboration with Ascent Partners Fund, which funded an additional $2 million tranche to establish a low-cost, capital-efficient Bitcoin treasury approach the company views as a digital store of value. Management framed the purchases as a foundation for progressing commercial and clinical programs.

#PFSA Profusa Invests Additional $1 Million in Digital Treasury Assets

www.stocktitan.net/news/PFSA/profusa-invest...

VesselAlert
Name: FWN ARCTIC
MMSI: 244130525
Callsign: PFSA
Type: Cargo
Flag: Netherlands
Seen: 27-Sep-2025 07:53:16 CEST
Status: under way using engine
Speed: 13.5 kts
Heading: 251 deg
Dest.: BE ANR
Distance: 34.3 nm
Signal RSSI: -15.0 dBFS
Ship AIS VesselAlert © kx1t - link

VesselAlert
Name: FWN ARCTIC
MMSI: 244130525
Callsign: PFSA
Type: Cargo
Flag: Netherlands
Seen: 27-Sep-2025 06:25:33 CEST
Status: under way using engine
Speed: 13.9 kts
Heading: 251 deg
Dest.: BE ANR
Distance: 33.6 nm
Signal RSSI: -26.7 dBFS
Ship AIS VesselAlert © kx1t - link

Betsy Southerland, a former director of the Office of Science and Technology in the EPA's Office of Water, said in a statement Friday: The impact of these chemicals is clear. We know that this is significant for pregnant women who are drinking water contaminated with PFAS, because it can cause low birth weight in children. We know children have developmental effects from being exposed to it. We know there's an increased incidence of cardiovascular disease and cancer with these chemicals. Two of the four chemicals targeted in this motion are the ones that we expect to be the most prevalent, and only increasing contamination in the future. With this rollback, those standards would be gone.

#ForeverChemicals #PFSA

Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring Profusa (NASDAQ:PFSA), a digital health company, has announced the integration of NVIDIA technology to develop an AI-powered insight portal for continuous biochemistry monitoring. The portal will combine Profusa's Lumee™ oxygen monitoring system with NVIDIA NeMo to enable advanced clinical workflows.The platform will feature an AI-driven physician portal with capabilities including EMR integration, remote monitoring, and a longitudinal health data graph that combines Profusa biomarkers with various health data sources. The system aims to provide real-time biochemistry monitoring and actionable clinical insights for healthcare providers.Profusa plans to launch the portal in early 2026 across the European Economic Area (EEA) where CE Mark certification is accepted.

#PFSA Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring

www.stocktitan.net/news/PFSA/profusa-adopts...

300+ CLTI Patients Annually: Profusa's Oxygen Monitoring Tech Enters Major Belgian Hospital Vascular surgeon Dr. Koen Deloose, treating 300+ CLTI patients yearly, adopts Profusa's Lumee Oxygen monitoring system. Partnership expands European presence for real-time tissue monitoring tech.

#PFSA Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base

www.stocktitan.net/news/PFSA/profusa-adds-h...

Conviction Rate in Pakistan: Challenges and Way Forward - Stratheia Pakistan’s conviction rate remains alarmingly low despite high arrests. Weak investigations, poor forensics, and oversight gaps undermine police credibility.

Forensic science is the missing link in Pakistan’s justice chain. Punjab leads with PFSA, while others lag dangerously behind.
#PFSA #Forensics #PoliceCredibility
stratheia.com/conviction-r...

Leading Vascular Center Adopts Profusa's Real-Time Oxygen Monitoring Tech for 1,500 Annual Procedures Digital health company Profusa collaborates with Prof. Brodmann at Medical University of Graz, implementing Lumee Oxygen platform across 1,500 annual vascular procedures. Partnership includes clinical studies.

#PFSA Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria

www.stocktitan.net/news/PFSA/profusa-announ...

Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O’Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO Profusa (NASDAQ: PFSA), a commercial stage digital health company, has announced two significant leadership appointments following its business combination with NorthView Acquisition Corp. Peter O'Rourke, former Acting U.S. Secretary of Veterans Affairs, joins as lead independent director, bringing experience from overseeing 1,300 facilities serving 9 million veterans.Additionally, Fred Knechtel, a seasoned Fortune 500 financial executive with experience at Northrop Grumman, Stanley Black & Decker, and DuPont, has been appointed as Chief Financial Officer. Both appointments aim to strengthen Profusa's commercialization efforts for its biosensor platform technology focused on continuous monitoring of individual biochemistry.

#PFSA Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O’Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

www.stocktitan.net/news/PFSA/profusa-welcom...

Profusa, Inc. Provides Strategy Overview and Business Update for Investors Profusa (NASDAQ: PFSA), a digital health company, has provided a comprehensive business update following its recent Nasdaq listing on July 14, 2025. The company outlined five strategic pillars: revenue growth, AI infrastructure, clinical/regulatory pathways, financial structure, and operational scale.Key developments include: $100 million ELOC facility secured for growth funding, planned European launch of Lumee™ platform for tissue oxygen monitoring in Q1 2026, targeting a $10 billion global addressable market. The company aims for U.S. FDA submission mid-2026 with commercialization expected in 2027. Their glucose monitoring platform, addressing a 500 million patient market, is progressing with human validation data expected from EU and APAC clinical sites, targeting commercialization by mid-2027.

#PFSA Profusa, Inc. Provides Strategy Overview and Business Update for Investors

www.stocktitan.net/news/PFSA/profusa-inc-pr...

Profusa Targets 300,000 Annual European Procedures with Spanish Distribution Partnership Profusa expands Lumee Oxygen platform to Spain through Dismeval partnership. New deal targets $10.5B global market opportunity. Learn expansion details.

#PFSA Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

www.stocktitan.net/news/PFSA/profusa-secure...

Digital Health Leader Makes Historic $1M Bitcoin Investment, Partners With BlockFills for Crypto Treasury Digital health innovator Profusa enters crypto market with million-dollar Bitcoin treasury strategy. See how this healthcare pioneer is embracing digital assets. Learn more.

#PFSA Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy

www.stocktitan.net/news/PFSA/profusa-announ...